F2 and autoimmune hemolytic anemia: The treatment of AHA reportedly consists of four pillars: prevention of bleeding; treatment of the underlying disease; hemostatic treatment using an FVIII agent, desmopressin, and bypassing agents (rFVIIa or activated prothrombin complex); and immunosuppressive therapy (e.g., steroids, cyclophosphamide and rituximab) for eradication of the inhibitor [1].